Figure 1

Figure 1: Overall Survival by Sequence and Formulation

Phase 2 study overall survival by sequence and formulation demonstrating extended OS with CPI at C1 and IP w/o IFNγ (Bria-IMT Phase 3 regimen)

Format

JPEG

Quelle:

BriaCell Therapeutics Corp.

Downloads